Schizophrenia Research

Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.

Schizophrenia Research Products Targets

Products for Schizophrenia Research - Page 5

  1. Cat.No. Product Name Information/Activity
  2. BCC7383 VUF 5681 dihydrobromide 639089-06-8 VUF 5681 dihydrobromide chemical structure
  3. BCC8013 C 21 Selective PRMT1 inhibitor C 21 chemical structure
  4. BCC8008 TC-E 5003 Selective PRMT1 inhibitor TC-E 5003 chemical structure
  5. BCC7640 8-(3-Chlorostyryl)caffeine 147700-11-6 8-(3-Chlorostyryl)caffeine chemical structure
  6. BCC6786 Bifemelane hydrochloride 62232-46-6 Bifemelane hydrochloride chemical structure
  7. BCC5196 R-(-)-Deprenyl hydrochloride R-(-)-Deprenyl Hydrochloride is a selective inhibitor of monoamine oxidase B (MAO-B). R-(-)-Deprenyl hydrochloride chemical structure
  8. BCN3998 Harman 486-84-0 Harman chemical structure
  9. BCC7371 Lazabemide hydrochloride 103878-83-7 Lazabemide hydrochloride chemical structure
  10. BCC2322 Moclobemide (Ro 111163) Moclobemide(Ro111163) is a reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Moclobemide (Ro 111163) chemical structure
  11. BCC6764 Pirlindole mesylate 207572-66-5 Pirlindole mesylate chemical structure

Items 41 to 50 of 709 total